Stock Research for PGNX

PGNX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

PGNX Stock Chart & Research Data

The PGNX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PGNX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


PGNX Due diligence Resources & Stock Charts

The PGNX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PGNX Detailed Price Forecast - CNN Money CNN View PGNX Detailed Summary - Google Finance
Yahoo View PGNX Detailed Summary - Yahoo! Finance Zacks View PGNX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View PGNX Trends & Analysis - Trade-Ideas Barrons View PGNX Major Holders - Barrons
NASDAQ View PGNX Call Transcripts - NASDAQ Seeking View PGNX Breaking News & Analysis - Seeking Alpha
Spotlight View PGNX Annual Report - CompanySpotlight.com OTC Report View PGNX OTC Short Report - OTCShortReport.com
TradeKing View PGNX Fundamentals - TradeKing Charts View PGNX SEC Filings - Bar Chart
WSJ View Historical Prices for PGNX - The WSJ Morningstar View Performance/Total Return for PGNX - Morningstar
MarketWatch View the Analyst Estimates for PGNX - MarketWatch CNBC View the Earnings History for PGNX - CNBC
StockMarketWatch View the PGNX Earnings - StockMarketWatch MacroAxis View PGNX Buy or Sell Recommendations - MacroAxis
Bullish View the PGNX Bullish Patterns - American Bulls Short Pains View PGNX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View PGNX Stock Mentions - StockTwits PennyStocks View PGNX Stock Mentions - PennyStockTweets
Twitter View PGNX Stock Mentions - Twitter Invest Hub View PGNX Investment Forum News - Investor Hub
Yahoo View PGNX Stock Mentions - Yahoo! Message Board Seeking Alpha View PGNX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for PGNX - SECform4.com Insider Cow View Insider Transactions for PGNX - Insider Cow
CNBC View PGNX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PGNX - OTC Markets
Yahoo View Insider Transactions for PGNX - Yahoo! Finance NASDAQ View Institutional Holdings for PGNX - NASDAQ


Stock Charts

FinViz View PGNX Stock Insight & Charts - FinViz.com StockCharts View PGNX Investment Charts - StockCharts.com
BarChart View PGNX Stock Overview & Charts - BarChart Trading View View PGNX User Generated Charts - Trading View




Latest Financial News for PGNX


What Does Nektar Therapeutics’ Valuation Trend Indicate?
Posted on Wednesday August 15, 2018

Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 


Analysts Remain Bullish on Nektar Stock in August
Posted on Tuesday August 14, 2018

Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.


Opko Health: Q2 Expenditures, Developments, Recommendations
Posted on Thursday August 09, 2018

In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency. In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1 and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.


How Opko Health Fared in the Second Quarter of 2018
Posted on Thursday August 09, 2018

In the second quarter, Opko Health reported a net loss of $6.2 million compared to a net loss of $16.9 million in Q2 2017. In the first half of 2018, it reported a net loss of $49.3 million compared to a net loss of $51.4 million in the first half of 2017. In the second quarter, it reported a diluted loss per share of $0.01 compared to a loss of $0.04 in Q2 2017. In the first half of 2018, it reported a diluted net loss per share of $0.09 compared to a diluted net loss per share of $0.11 in the first half of 2017.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.